Aims To examine the relationship between changes in electronic cigarette (e-cigarette) use and subsequent cigarette smoking cessation.
Methods Using data from the Population Assessment of Tobacco and Health Study (wave 1–wave 4), we analysed a study cohort of 3014 current adult cigarette smokers at wave 1 who tried to quit during the past 12 months. We categorised changes in e-cigarette use from wave 1 to wave 2 as: daily initiation, non-daily initiation, increase to daily use, increase to non-daily use, stable daily use, stable non-daily use, decrease from daily use, quit non-daily use and non-use. We estimated multivariable logistic regressions on short-term (≥1 month and <12 months) cigarette smoking cessation at wave 3 and long-term (≥12 months) cigarette smoking cessation at wave 4. We conducted sensitivity analyses using alternative study cohorts.
Results Among the study cohort, 2.4% initiated daily, 7.5% initiated non-daily, 1.0% increased to daily, 1.4% increased to non-daily, 1.5% maintained daily, 3.0% maintained non-daily, 2.4% decreased from daily and 3.8% quit non-daily e-cigarette use between waves 1 and 2; 7.9% and 6.9% reported short-term and long-term cigarette smoking cessation. 15.1% of short-term and 16.3% of long-term cigarette quitters used e-cigarettes. Compared with non-users, smokers who initiated daily, increased to daily or quit non-daily e-cigarette use between waves 1 and 2 had higher odds of short-term cigarette smoking cessation at wave 3. These results are robust to different study cohort specifications.
Conclusion The findings suggest a complex relationship between changes in e-cigarette use and subsequent cigarette smoking cessation.
- electronic nicotine delivery devices
Data availability statement
No data are available. This study used the public available Population Assessment of Tobacco and Health (PATH) study data.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors YW planned the study. YW, H-YS and WBM designed the methodology. YW conducted literature review and the statistical analysis. YW wrote the original draft of the manuscript. YW, H-YS and WBM reviewed, edited and revised the manuscript. YW is reponsible to the overall content as a guarantor.
Funding This work was supported by grant number P0517556 (A127877) from the National Cancer Institute (NCI) at the NIH and the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) and by grant number U54 HL147127 from the National Heart, Lung, and Blood Institute (NHLBI) and FDA's CTP.
Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI, NHLBI or FDA.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.